NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from HXNet? Mail in a sample (US only) and let us test it.

Test my supply
+4 more ↓
72%
Finnrick rating
#284 of 500 ranked vendors
146 of 175 classifiable tests passed
methodology · Purity focus
Finnrick analysis

HXNet's purity-focus record is strongest in Tirzepatide and GHK-Cu, with Retatrutide adding a large but more volatile evidence base. Weakness clusters in Tesamorelin, Cagrilintide, and TB-500, where purity or fill misses and uneven batch IDs make the recent improvements less settled.

methodology →
vendor intelligence report
Vendor Intelligence Report: HXNet

Chinese registry snippets show the ChemicalBook anchor entity was cancelled before the current sales run. The report maps the HXTNT/LaraPharma channel shift, lookalike web infrastructure, and COA files that reuse third-party lab identifiers.

41 pages5 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.04
90%
14
2
Tirzepatide
$0.35
89%
52
3
Retatrutide
$0.60
83%
49
4
Semaglutide
$1.00
76%
5
6
BPC-157
$0.60
67%
10
7
PT-141
$0.50
64%
2
8
Cagrilintide
$1.76
62%
15
9
Tesamorelin
$1.80
54%
12
10
CJC-1295
-
49%
5
11
Sermorelin
-
49%
3
12
TB-500
$1.36
48%
6
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%2 May 2026: 68%2 May 2026: 68%8 May 2026: 68%8 May 2026: 69%11 May 2026: 69%11 May 2026: 69%13 May 2026: 69%13 May 2026: 69%13 May 2026: 69%15 May 2026: 69%15 May 2026: 69%18 May 2026: 70%21 May 2026: 70%27 May 2026: 69%2 Jun 2026: 69%2 Jun 2026: 69%2 Jun 2026: 69%2 Jun 2026: 69%4 Jun 2026: 69%6 Jun 2026: 70%6 Jun 2026: 70%12 Jun 2026: 70%24 Jun 2026: 70%26 Jun 2026: 70%1 Jul 2026: 70%13 Jul 2026: 70%13 Jul 2026: 70%20 Jul 2026: 70%9 Aug 2026: 71%12 Aug 2026: 71%15 Aug 2026: 71%24 Sep 2026: 72%24 Sep 2026: 72%24 Sep 2026: 72%24 Sep 2026: 72%12 Oct 2026: 72%13 Oct 2026: 72%23 Oct 2026: 72%23 Oct 2026: 72%23 Oct 2026: 72%15 Nov 2026: current 72%68%70%72%May 26Nov 26
Peptide testing

Ordered peptides from HXNet? Mail in a sample (US only) and let us test it.

Test my supply
HXNet test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
23 Oct 2026
Pass
BPC-157
lab nameView COA
23 Oct 2026
Pass
GHK-Cu
lab nameView COA
23 Oct 2026
Pass
TB-500
lab nameView COA
13 Oct 2026
Pass
Retatrutide
lab nameView COA
12 Oct 2026
Pass
Retatrutide
lab nameView COA
24 Sep 2026
Pass
GHK-Cu
lab nameView COA
24 Sep 2026
Pass
GHK-Cu
lab nameView COA
24 Sep 2026
Pass
CJC-1295 (No DAC)
lab nameView COA
24 Sep 2026
Pass
Retatrutide
lab nameView COA
15 Aug 2026
Pass
Sermorelin
lab nameView COA
1-10 of 178

About HXNet test results from Finnrick

HXNet is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 178 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible HXNet peptides in this dataset are Tirzepatide (52 tests), Semaglutide (5 tests) and BPC-157 (10 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 178 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from HXNet? Mail in a sample (US only) and let us test it.

Test my supply